Crucell N.V. has entered into an exclusive vaccine development agreement with Wyeth Pharmaceuticals. Under the terms of the agreement, Crucell will be responsible for the development and manufacture of certain components of a vaccine for use in Wyeth clinical studies. The development activities will take place in Crucell’s vaccine manufacturing facilities in Bern, Switzerland. Wyeth will be responsible for the clinical development of the vaccine. Financial details were not disclosed....